Bulk RNA-seq of Genetically Diverse Triple-Negative Breast Cancer Mouse Models Treated with Immunotherapy, Chemotherapy, Erlotinib, or Trametinib

Tumors were harvested from mice that were either untreated or treated with immunotherapy (anti-PD-1 and anti-CTLA-4), chemotherapy (Carboplatin + Paclitaxel), EGFR inhibition (Erlotinib), or MEK inhibition (Trametinib) for 7 days. Each model represents a distinct transcriptional subtype and genetic background, enabling the assessment of intertumoral heterogeneity in treatment response.

This dataset includes RNA-seq from 2-9 biological replicates per model per condition. Tumor samples were collected prior to or during treatment response assessment, and are accompanied by corresponding survival from similarly-treated tumors. All sequencing was performed on polyA-selected RNA using Illumina platforms.